|
|
Post by louaboardalia on Apr 10, 2020 18:49:11 GMT -5
|
|
|
|
Post by cjm18 on Apr 10, 2020 19:31:43 GMT -5
|
|
|
|
Post by louaboardalia on Apr 10, 2020 20:41:01 GMT -5
Thanks...
|
|
|
|
Post by JEvans on Apr 10, 2020 20:51:44 GMT -5
After reading Sched 14A that is to be voted on by Shareholders at the Annual Mtg of Shareholders on May 21, 2020. It seems very wrong that that MNKD and its BOD have agreed and recommend the following:
PROPOSAL 1 - Election of Directors
-Kent Kresa (1)(2) Age 82 Chairman of the Board of Directors
-Michael E. Castagna, Pharm.D. Age 43 Chief Executive Officer and Director
-Ronald J. Consiglio(2)(3) Age 76 Director
-Michael A. Friedman, M.D.(1)(2) Age 76 Director
-Jennifer Grancio(3) Age 48 Director
-Anthony Hooper(3) Age 65 Director
-Christine Mundkur(3) Age 51 Director
-James S. Shannon, M.D., MRCP (UK)(1) Age 63 Director
(1) Member of the Compensation Committee.
(2) Member of the Nominating and Corporate Governance Committee.
(3) Member of the Audit Committee.
PROPOSAL 2
- APPROVAL OF INCREASE IN NUMBER OF AUTHORIZED SHARES OF COMMON STOCK
-MannKind’s Board of Directors is requesting stockholder approval to increase the Company’s authorized number of shares of common stock from 280,000,000 shares to 400,000,000 shares.
PROPOSAL 3
- APPROVAL OF AN AMENDMENT TO THE 2018 EQUITY INCENTIVE PLAN
- To increase the number of shares of common stock authorized for issuance (to the failing Executive Officers and Board of Directors) under the 2018 Plan by 12,500,000 shares.
PROPOSAL 4
- ADVISORY VOTE ON EXECUTIVE COMPENSATION
- To Increase the millions of $ already being paid to the failing executives such as Michael Castagna and the failing Board of Directors.
Why would anyone in their right mind want to increase the pay of the complete failure of executives and the board of directors to add value to the company they seek more compensation from?
They are failures at their job based on years of failing stock prices, and failing scripts....Period.
|
|
|
|
Post by akemp3000 on Apr 10, 2020 21:19:28 GMT -5
Yawn...All gets approved. The company keeps improving year over year as it's been doing.
|
|
|
|
Post by JEvans on Apr 10, 2020 21:58:55 GMT -5
Yawn...All gets approved. The company keeps improving year over year as it's been doing. Last yr, 14th week of 2019 - Trx 630, Stock price 1.79 Current, 14th week of 2020 - Trx 670, Stock price 1.04 |
|
|
|
Post by mnkdfann on Apr 10, 2020 22:45:00 GMT -5
After reading Sched 14A that is to be voted on by Shareholders at the Annual Mtg of Shareholders on May 21, 2020. It seems very wrong that that MNKD and its BOD have agreed and recommend the following: PROPOSAL 1 - Election of Directors -Kent Kresa (1)(2) Age 82 Chairman of the Board of Directors -Michael E. Castagna, Pharm.D. Age 43 Chief Executive Officer and Director -Ronald J. Consiglio(2)(3) Age 76 Director -Michael A. Friedman, M.D.(1)(2) Age 76 Director -Jennifer Grancio(3) Age 48 Director -Anthony Hooper(3) Age 65 Director -Christine Mundkur(3) Age 51 Director -James S. Shannon, M.D., MRCP (UK)(1) Age 63 Director (1) Member of the Compensation Committee.
(2) Member of the Nominating and Corporate Governance Committee.
(3) Member of the Audit Committee.If this was discussed elsewhere I missed it, but I guess this means that none of the individuals Hope for Mannkind nominated were accepted as candidates? |
|
|
|
Post by longliner on Apr 10, 2020 23:08:54 GMT -5
Yawn...All gets approved. The company keeps improving year over year as it's been doing. It is within a few shares of what my alter ego predicted for CFBE. (Please check if it bugs you). Yawn |
|
|
|
Post by Actual Investor on Apr 11, 2020 0:44:13 GMT -5
JEvans,
If what you wrote was in fact the proposed action of the BOD you might have something worth reading. Since what is written in your post is your biased description of the proposed items, it would be best if everyone just ignored your post and read the two document for themselves.
|
|
|
|
Post by cjm18 on Apr 11, 2020 8:31:53 GMT -5
Yawn...All gets approved. The company keeps improving year over year as it's been doing. Last yr, 14th week of 2019 - Trx 630, Stock price 1.79 Current, 14th week of 2020 - Trx 670, Stock price 1.04 Too much noise picking just one week. Better to compare a 2020 month to a 2019 month before the virus hit. Maybe even just look at nrx. Can’t grow If not adding patients. |
|
|
|
Post by mango on Apr 11, 2020 9:46:50 GMT -5
It is financially irresponsible, not warranted nor justified for MannKind Executive Management to seek increased compensation for their performance in 2019. Not only was their performances mediocre and stayed well within the boundaries of their given job duties (none of them went above and beyond), and not only have MannKind Shareholders not received an ROI, and not only is MannKind strapped for cash, and not only is MannKind still in massive debt, and not only is MannKind still in financial arrangements with swamp creatures, and not only is the PPS at a pathetic $1.04—but the Country is in a grand economic meltdown and in the midst of a global pandemic. This is financial irresponsibility. This is financial immaturity. This is financial greed. This is disrespectful to MannKind Shareholders, employees, the Company, patients and the late Alfred E. Mann. I am extremely disappointed in MannKind Executive Management. Sign this Petition if you agree. www.change.org/p/mannkind-shareholders-mannkind-shareholders-against-salary-increases-and-bonuses-for-executive-management |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 11, 2020 10:24:20 GMT -5
It is financially irresponsible, not warranted nor justified for MannKind Executive Management to seek increased compensation for their performance in 2019. Not only was their performances mediocre and stayed well within the boundaries of their given job duties (none of them went above and beyond), and not only have MannKind Shareholders not received an ROI, and not only is MannKind strapped for cash, and not only is MannKind still in massive debt, and not only is MannKind still in financial arrangements with swamp creatures, and not only is the PPS at a pathetic $1.04—but the Country is in a grand economic meltdown and in the midst of a global pandemic. This is financial irresponsibility. This is financial immaturity. This is financial greed. This is disrespectful to MannKind Shareholders, employees, the Company, patients and the late Alfred E. Mann. I am extremely disappointed in MannKind Executive Management. Sign this Petition if you agree. www.change.org/p/mannkind-shareholders-mannkind-shareholders-against-salary-increases-and-bonuses-for-executive-managementOK - Let's all complain about the 2% Raise in Mike's Salary. That's worth about 40 posts. Instead of only looking at the stock price look at the accomplishments that have transpired in 2019. The foundation is being laid within MNKD. Brazil was approved and Sales are being recorded. I don't mind the executive compensation incentives. If you look at DXCM's S-4's you will blow your mind. Early on their executives were paid in options and they have done well. The same will happen with MNKD. A CEO that makes $500,000 in salary is very reasonable and let's not forget they are a GLOBAL PHARMA Company now. But then again you will complain about the salary and the stock options. You have to compensate talent or you will not attract nor retain talent. IMO MNKD will issue more stock options after the ASM and then the floor will be in. I expect the stock price to head north. Also the increase in AS is for possible equity partners. They will have about 35% to issue but the key is for the stock price to be higher and then make the deal. Mike & Co. have a plan. The last 3 years were tough. MNKD was a mess but the hard work is done and now it's the time to reap some benefits. There are several important events happening this year that will propel the stock price. Yes the PANDEMIC has caused a speed bump but this too shall pass. If you haven't noticed 10 Million SHORT SHARES have been covered over the last month. That should tell you something. OBTW - For those who think a MOASS will happen......NOT. 10M shares covered and the stock increased $.10 CENTS |
|
|
|
Post by mango on Apr 11, 2020 10:32:19 GMT -5
Merely doing your job does not warrant, nor justify, compensation increases.
Sickening.
|
|
|
|
Post by goyocafe on Apr 11, 2020 11:20:09 GMT -5
Does Casper work for Mannkind Corporation? Casper, just look at the irregular ratings they gave themselves relative to their goals. I won’t spell them all out again. They insult my aging intelligence. If you think claiming a 22% increase in share price is an example of “talent”, I have to wonder what shit show I’m watching. Sorry, I don’t buy the justifications you’ve given. Compensate management when they show measurable results that do not insult anyone outside of the organization and I’m all for it. Where are the results? Sales up 40%? Hell, double them and it might get my attention, except they are still paltry relative to what is needed. The cash on hand is a slight of hand. Dilute in December, 2018, and get get credit for remaining cash the following year doesn’t fool me. Shareholders paid for that cash, not company management performance.
|
|
|
|
Post by mango on Apr 11, 2020 11:50:03 GMT -5
Does Casper work for Mannkind Corporation? Casper, just look at the irregular ratings they gave themselves relative to their goals. I won’t spell them all out again. They insult my aging intelligence. If you think claiming a 22% increase in share price is an example of “talent”, I have to wonder what shit show I’m watching. Sorry, I don’t buy the justifications you’ve given. Compensate management when they show measurable results that do not insult anyone outside of the organization and I’m all for it. Where are the results? Sales up 40%? Hell, double them and it might get my attention, except they are still paltry relative to what is needed. The cash on hand is a slight of hand. Dilute in December, 2018, and get get credit for remaining cash the following year doesn’t fool me. Shareholders paid for that cash, not company management performance. Don't worry, I have it and it is worth repeating. • $40M of cash on hand in 2019 was acquired via the 2018 Christmas Massacre • How convenient and yet totally disingenuous to use cash derived from toxic financing as a basis for a corporate objective that was established only a few months later. • Without knowing about any real business development or clinical advancement other than what was expected of them for just doing their jobs, it’s hard to see how a merit increase or bonus fits, but here’s a first blush at a more comprehensive set of objectives. ----------------------- Weight Earned • Net Sales 9/40 • Cash 15/15 • Business Development 10/15 • Progress Clinical 15/15 • Shareholder ROI -30/15 • Net score = 24% If you are disappointed with MannKind Executive Management seeking salary increases and/or bonuses for a mediocre 2019 performance—during an economic meltdown and global pandemic—then sign the MannKind Shareholders Petition to let them know you disagree with their scoring system and their financial irresponsibility. MannKind Executive Management is being financially irresponsible and selfish during an economic meltdown and global pandemic. Sign the Petition if you sick and tired of this kind of mistreatment by MannKind Executive Management. www.change.org/p/mannkind-shareholders-mannkind-shareholders-against-salary-increases-and-bonuses-for-executive-management |
|
